Macular Degeneration Treatment Market Size (2024 - 2029)

The macular degeneration treatment market is projected to experience significant growth over the forecast period, driven by an increasing prevalence of retinal disorders and a rising geriatric population. The market's expansion is further supported by heightened research and development activities and clinical trials, which are crucial for advancing treatment options. Despite these growth drivers, challenges such as the use of off-label drugs and a lack of awareness about the disease pose potential obstacles to market expansion.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Developmental Anomalities Research Macular Degeneration Treatment Market Market Size

Market Size of Macular Degeneration Treatment Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Macular Degeneration Treatment Market Summary
Study Period 2021 - 2029
Market Size (2024) USD 15.47 Billion
Market Size (2029) USD 23.29 Billion
CAGR (2024 - 2029) 8.51 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Macular Degeneration Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Macular Degeneration Treatment Market Analysis

The Macular Degeneration Treatment Market size is estimated at USD 15.47 billion in 2024, and is expected to reach USD 23.29 billion by 2029, growing at a CAGR of 8.51% during the forecast period (2024-2029).

The COVID-19 pandemic had potential economic impact and implications for most sectors, including the pharmaceutical and biotech industries. For instance, according to a research study published in the SN Comprehensive Clinical Medicine Journal in October 2020, the number of clinic visits for intravitreal injections (IVI) in the treatment of macular degeneration during one month from March 15 to April 14 of 2020 was compared to a similar time period in each of the last four years. The study demonstrated a decrease in clinic visits for intravitreal injections (IVI) compared with the same 4-week interval in the four previous years, and a total of 636 eyes received injections during a 4-week period of the COVID-19 outbreak in the Retina Clinic, Israel, in 2020, as compared to 995 injections in 2019. However, the easing of norms and the start of vaccination programs led to a recovery in the macular degeneration market.

The major factors attributing to the growth of the macular degeneration treatment market are the increasing burden of retinal disorders, the upsurge in the geriatric population, and an increase in research and development investments.

The increasing burden of retinal disorders is driving the market's growth. For instance, according to a research article published in the British Journal of Ophthalmology in August 2020, in Europe, age-related macular degeneration (AMD) is the main cause of visual impairment and blindness. About 67 million people in Europe are affected by age-related macular degeneration (AMD), and due to population aging, this number is expected to increase by 15% until 2050. As per the statistics, the increasing number of individuals with retinal disorders is directly proportional to market growth. Thus, the increasing burden of such disorders is driving the demand for macular degeneration treatment, which is further contributing to market growth.

Moreover, increasing research and development (R&D) and increasing clinical trials are other major factors for market growth. For instance, in November 2022, 4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced interim clinical data from cohort 1 of the Phase I/II clinical trial of intravitreal 4D-150 for wet AMD. The data focused on safety, tolerability, aflibercept transgene expression, and anti-VEGF clinical activity of the 4D-150 genetic medicine in patients enrolled in Cohort 1. Moreover, in January 2021, Novartis AG started a phase III clinical trial to evaluate the efficacy and safety of brolucizumab in patients with neovascular age-related macular degeneration. Such developments are fueling the growth of the macular degeneration market.

However, the increasing use of off-label drugs and lack of awareness regarding the disease are the major restraints on the growth of the market.

Macular Degeneration Treatment Industry Segmentation

As per the scope of the report, macular degeneration is a retinal disorder affecting older people. The early stages of the disease (early and intermediate AMD) are generally asymptomatic, and they gradually progress to the late stages of the disease, which may cause severe visual loss. Type (Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration), Stage of Disease (Early-stage AMD, Intermediate AMD, and Late-stage AMD), Treatment Type (Drug, Devices, Surgery), Route of Administration (Intravenous Route and Intravitreal Route), Sales Channel (Ambulatory Surgical Centers, Hospitals, and Other Sales Channels), and Geography (North America, Europe, Asia). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
By Stage of Disease
Early-stage AMD
Intermediate AMD
Late-stage AMD
By Treatment Type
Drug
Anti-vascular Endothelial Growth Factor
Dietary Supplements
Other Drugs
Devices
Glasses
Contact Lenses
Other Devices
Surgery
Laser Surgery
Other Surgeries
By Route of Administration
Intravenous Route
Intravitreal Route
By Sales Channel
Ambulatory Surgical Centers
Hospitals
Other Sales Channels
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Macular Degeneration Treatment Market Size Summary

The macular degeneration treatment market is poised for significant growth, driven by an increasing prevalence of retinal disorders and a rising geriatric population. The market is experiencing a resurgence following the COVID-19 pandemic, which had initially disrupted treatment protocols but has since recovered due to eased restrictions and vaccination efforts. The demand for effective treatments is further bolstered by substantial investments in research and development, leading to advancements in clinical trials and the introduction of innovative therapies. The market is characterized by a competitive landscape, with major players like Novartis AG and F Hoffmann-La Roche Ltd actively engaging in product launches and strategic collaborations to enhance their market share.

The market's expansion is particularly notable in the North American region, where the aging population and the prevalence of age-related macular degeneration are significant contributors to market growth. The presence of key industry players, coupled with supportive government initiatives and research partnerships, is expected to drive further advancements and product availability. Despite challenges such as the use of off-label drugs and limited awareness, the market continues to thrive, with wet macular degeneration treatments holding a substantial share. The introduction of biosimilars and novel therapies is anticipated to further propel the market, addressing the growing need for effective interventions in managing macular degeneration.

Explore More

Macular Degeneration Treatment Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Burden of Retinal Disorders

      2. 1.2.2 Upsurge in the Geriatric Population

      3. 1.2.3 Increase in Research and Development Investments

    3. 1.3 Market Restraints

      1. 1.3.1 Increasing Use of Off-label Drugs

      2. 1.3.2 Lack of Awareness Regarding AMD

    4. 1.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Buyers/Consumers

      2. 1.4.2 Bargaining Power of Suppliers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Value By Size - USD Million)

    1. 2.1 By Type

      1. 2.1.1 Dry Age-related Macular Degeneration

      2. 2.1.2 Wet Age-related Macular Degeneration

    2. 2.2 By Stage of Disease

      1. 2.2.1 Early-stage AMD

      2. 2.2.2 Intermediate AMD

      3. 2.2.3 Late-stage AMD

    3. 2.3 By Treatment Type

      1. 2.3.1 Drug

        1. 2.3.1.1 Anti-vascular Endothelial Growth Factor

        2. 2.3.1.2 Dietary Supplements

        3. 2.3.1.3 Other Drugs

      2. 2.3.2 Devices

        1. 2.3.2.1 Glasses

        2. 2.3.2.2 Contact Lenses

        3. 2.3.2.3 Other Devices

      3. 2.3.3 Surgery

        1. 2.3.3.1 Laser Surgery

        2. 2.3.3.2 Other Surgeries

    4. 2.4 By Route of Administration

      1. 2.4.1 Intravenous Route

      2. 2.4.2 Intravitreal Route

    5. 2.5 By Sales Channel

      1. 2.5.1 Ambulatory Surgical Centers

      2. 2.5.2 Hospitals

      3. 2.5.3 Other Sales Channels

    6. 2.6 Geography

      1. 2.6.1 North America

        1. 2.6.1.1 United States

        2. 2.6.1.2 Canada

        3. 2.6.1.3 Mexico

      2. 2.6.2 Europe

        1. 2.6.2.1 Germany

        2. 2.6.2.2 United Kingdom

        3. 2.6.2.3 France

        4. 2.6.2.4 Italy

        5. 2.6.2.5 Spain

        6. 2.6.2.6 Rest of Europe

      3. 2.6.3 Asia-Pacific

        1. 2.6.3.1 China

        2. 2.6.3.2 Japan

        3. 2.6.3.3 India

        4. 2.6.3.4 Australia

        5. 2.6.3.5 South Korea

        6. 2.6.3.6 Rest of Asia-Pacific

      4. 2.6.4 Middle-East and Africa

        1. 2.6.4.1 GCC

        2. 2.6.4.2 South Africa

        3. 2.6.4.3 Rest of Middle-East and Africa

      5. 2.6.5 South America

        1. 2.6.5.1 Brazil

        2. 2.6.5.2 Argentina

        3. 2.6.5.3 Rest of South America

Macular Degeneration Treatment Market Size FAQs

The Macular Degeneration Treatment Market size is expected to reach USD 15.47 billion in 2024 and grow at a CAGR of 8.51% to reach USD 23.29 billion by 2029.

In 2024, the Macular Degeneration Treatment Market size is expected to reach USD 15.47 billion.

Macular Degeneration Treatment Market Report Snapshots

Macular Degeneration Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)